Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Sep 5:362:k3581.
doi: 10.1136/bmj.k3581.

Prostate cancer screening with prostate-specific antigen (PSA) test: a clinical practice guideline

Affiliations

Prostate cancer screening with prostate-specific antigen (PSA) test: a clinical practice guideline

Kari A O Tikkinen et al. BMJ. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Competing interests: All authors have completed the BMJ Rapid Recommendations interests disclosure form, and a detailed description of all disclosures is reported in appendix 1. As with all BMJ Rapid Recommendations, the executive team and The BMJ judged that no panel member had any financial conflict of interest. Professional and academic interests are minimised as much as possible, while maintaining necessary expertise on the panel to make fully informed decisions.

Figures

Fig 2
Fig 2
Characteristics of patients and trials included in systematic review of the use of the prostate-specific antigen (PSA) test for prostate cancer screening.
Fig 3
Fig 3
Practical issues about use of prostate-specific antigen (PSA) testing and biopsy for prostate cancer screening

Comment in

Similar articles

Cited by

References

    1. Ilic D, Djulbegovic M, Jung JH, et al. Prostate cancer screening with prostate-specific antigen (PSA) test: a systematic review and meta-analysis. BMJ 2018;362:k3519 10.1136/bmj.k3519. - DOI - PMC - PubMed
    1. Martin RM, Donovan JL, Turner EL, et al. CAP Trial Group Effect of a low-intensity PSA-based screening intervention on prostate cancer mortality: The CAP Randomized Clinical Trial. JAMA 2018;319:883-95. 10.1001/jama.2018.0154 - DOI - PMC - PubMed
    1. Global Burden of Disease Cancer Collaboration The Global burden of cancer 2013. JAMA Oncol 2015;1:505-27. 10.1001/jamaoncol.2015.0735. - DOI - PMC - PubMed
    1. Østerø Í Jákupsstovu J, Brodersen J. Do men with lower urinary tract symptoms have an increased risk of advanced prostate cancer? BMJ 2018;361:k1202. 10.1136/bmj.k1202. - DOI - PubMed
    1. Schröder FH, Hugosson J, Roobol MJ, et al. ERSPC Investigators Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet 2014;384:2027-35. 10.1016/S0140-6736(14)60525-0. - DOI - PMC - PubMed

Publication types

MeSH terms

Substances